Prem Premsrirut
Vorstandsvorsitzender bei Mirimus, Inc.
Profil
Prem Premsrirut is the founder of Mirimus, Inc., which she founded in 2010 and where she currently holds the title of President & Chief Executive Officer.
She is also currently employed as the Director at New York Biotechnology Association, Inc.
Aktive Positionen von Prem Premsrirut
| Unternehmen | Position | Beginn |
|---|---|---|
New York Biotechnology Association, Inc.
 New York Biotechnology Association, Inc. Miscellaneous Commercial ServicesCommercial Services New York Biotechnology Association, Inc. promotes the biotechnology industry. It supports the development and growth of New York State''s life science industry, and serves its members and the life science community by providing a network for public policy, industry advocacy, and community development. The company is headquartered in New York, NY. | Direktor/Vorstandsmitglied | - |
Mirimus, Inc.
 Mirimus, Inc. Medical SpecialtiesHealth Technology Mirimus, Inc. is a private company based in Brooklyn, NY that specializes in creating animal models for preclinical evaluation of new therapeutics. The company uses rnai and crispr technologies to develop these models and have established themselves as a leader in conducting high-volume, complex and highly effective pcr testing. Mirimus has developed SalivaClear, a COVID-19 testing platform that combines saliva-based sampling, pooled testing, and pcr diagnostics to improve the scalability, efficiency, cost-effectiveness, and accuracy of COVID-19 testing. The company was founded in 2010 by Stephen Elledge, Prem Premsrirut, Lukas Dow, Christof Fellman, Greg Hannon, Scott W. Lowe, Johannes Zuber, and Prem Premsrirut has been the CEO since 2010. | Vorstandsvorsitzender | 01.01.2010 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Mirimus, Inc.
Mirimus, Inc. Medical SpecialtiesHealth Technology Mirimus, Inc. is a private company based in Brooklyn, NY that specializes in creating animal models for preclinical evaluation of new therapeutics. The company uses rnai and crispr technologies to develop these models and have established themselves as a leader in conducting high-volume, complex and highly effective pcr testing. Mirimus has developed SalivaClear, a COVID-19 testing platform that combines saliva-based sampling, pooled testing, and pcr diagnostics to improve the scalability, efficiency, cost-effectiveness, and accuracy of COVID-19 testing. The company was founded in 2010 by Stephen Elledge, Prem Premsrirut, Lukas Dow, Christof Fellman, Greg Hannon, Scott W. Lowe, Johannes Zuber, and Prem Premsrirut has been the CEO since 2010. | Health Technology |
New York Biotechnology Association, Inc.
New York Biotechnology Association, Inc. Miscellaneous Commercial ServicesCommercial Services New York Biotechnology Association, Inc. promotes the biotechnology industry. It supports the development and growth of New York State''s life science industry, and serves its members and the life science community by providing a network for public policy, industry advocacy, and community development. The company is headquartered in New York, NY. | Commercial Services |
